Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab plus Brentuximab Vedotin in Advanced Classical Hodgkin Lymphoma
NCT03138499Phase 3Terminated
- Sponsor
- Bristol Myers Squibb
- Start
- Jun 2017
- Primary completion
- Feb 2021
- Modality
- Monoclonal Antibodies
- Countries
- 3
01
Overview
A Phase 3 trial of nivolumab in classical Hodgkin lymphoma (cHL), sponsored by Bristol Myers Squibb. Started Jun 2017; status: terminated.
02
Drugs
03
Conditions
classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on NCT03138499.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03138499.